# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple...
-8-K
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Voyager Therapeutics (NASDAQ:VYGR) with a Buy rating and annou...
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising...
HC Wainwright & Co. analyst Patrick Trucchio initiates coverage on Voyager Therapeutics (NASDAQ:VYGR) with a Buy rating ...